Friday, November 13, 2026

GBP/EUR Drops By 1% In The Last 21 Sessions

ViaNews Editorial Team

February 17, 2023

Automated market report from our archive (2020–2024), published before source-traceability. How we work

GBP/EUR Drops By 1% In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.77% for the last 21 sessions. At 07:06 EST on Friday, 17 February, GBP/EUR (GBPEUR) is $1.12.

GBP/EUR's yearly highs and lows, it's 3.875% up from its 52-week low and 7.844% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.17%, a negative 0.01%, and a positive 0.32%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.17% (last week), 0.36% (last month), and 0.32% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy price analysis: bulls flirt with 133.00 inside monthly rising wedge. According to FXStreet on Wednesday, 15 February, "It should be noted that the 130.00 round figure will act as an extra filter towards the south of 130.60 before directing the USD/JPY sellers towards the theoretical target of the stated wedge, namely 125.50.", "Even if the quote rises past 133.60, a two-month-old horizontal resistance region near 134.50-70, will precede the 200-DMA level surrounding 136.90 to challenge the USD/JPY bulls."
  • Usd/jpy snaps two-day uptrend despite upbeat yields, hawkish fed talks. According to FXStreet on Wednesday, 15 February, "Moving on, a lack of major data/events from Japan puts the USD/JPY pair at the mercy of the US catalysts for clear directions. ", "Unless providing a daily close beyond the 200-day Exponential Moving Average (EMA), the USD/JPY pair remains on the bear's radar."
  • Usd/jpy: correction from six-week highs stalls near 132.50, US data eyed. According to FXStreet on Wednesday, 15 February, "The rush to safety in the US bond market is sending the US Treasury bond yields lower, in turn, weighing down on the USD/JPY pair.", "From a short-term technical perspective, USD/JPY is reattempting the 133.00 level, having found support near the 132.50 psychological level."
  • Usd/jpy price analysis: back above 134.00, as bulls moved in and crushed the 200-dma. According to FXStreet on Wednesday, 15 February, "Nevertheless, the USD/JPY needs to clear the confluence of the 100-day EMA and the YTD high at 134.77 to cement the uptrend.", "The USD/JPY rallies more than 100 pips and clears the 134.00 mark, breaking north of the 200-day Exponential Moving Average (EMA) at 133.77, a bullish/bearish bias measure for an asset. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com